FDA expands Qulipta indication to include chronic migraine prevention

[cafead]

via Qulipta, an oral CGRP receptor antagonist, has been approved to prevent chronic and episodic migraine in adults.
FDA approval was based on positive results from the phase 3 PROGRESS trial.

article source